Episode Details

Most conversations about longevity focus on metabolism, inflammation, or cellular senescence. Far fewer address what may be one of the most consequential drivers of biological ageing: the slow, decades-long collapse of immune function. The thymus begins involuting in early puberty and is largely inactive by 60, leaving behind a shrinking T cell pool, blunted vaccine responses, reduced cancer immune surveillance, and chronic low-grade inflammation. This is immunosenescence — and its association with all-cause mortality in longitudinal data is well established.

Thymosin Alpha-1 is the primary bioactive peptide the thymus produces. First isolated in the 1970s, the synthetic version has been in clinical use for decades and is approved in over 35 countries. In this episode, Dr. Ethan covers the full picture: the mechanism, the Phase III trial data across hepatitis and sepsis, the vaccine potentiation findings in elderly populations, the regulatory reality in the UK and EU, and the honest gaps that remain around its longevity-specific application. TA-1 is unusual in this space — not a compound with a compelling story and thin evidence, but one with substantial clinical data and a longevity application that is mechanistically coherent but formally undertested. That distinction matters, and this episode explains why.